ClinicalTrials.gg
TerminatedNCT02138786SIRRTUpdated Jan 26, 2023Results posted

Selinexor in Initial or Refractory and/or Relapsed Richter's Transformation

A Phase 2 interventional study of selinexor in Richter's Transformation, sponsored by Karyopharm Therapeutics Inc. Terminated at 17 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-01-26.

Sponsored by Karyopharm Therapeutics Inc · Phase 2, Interventional, and Treatment

Why this study was terminated
Lack of efficacy at time of interim analysis

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
27
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

This is a multi-center, phase 2, single arm, open-label study of oral selinexor monotherapy in patients with Richter's Transformation, arising in the setting of prior chronic lymphocytic leukemia (CLL), after at least one chemo-immunotherapy regimen for CLL.

Read the detailed description

Multi-center, phase 2, single arm, open-label study of oral selinexor monotherapy in patients with Richter's Transformation, arising in the setting of prior CLL, documented by histologically confirmed lymphoma, including diffuse large B-cell (DLBCL) and immunoblastic variants. Eligible patients must have had at least one prior regimen for CLL. Approximately 50 patients are anticipated to be treated in this study. Eligible patients following screening will receive selinexor orally twice weekly at a dose of 60 mg. The selinexor dose may be increased to 80 mg after Cycle 1 unless clinically contraindicated. Patients may continue in multiple treatment cycles at a given dose; there is no maximum treatment duration. Each cycle is 28 days. Dose adjustments will be made as appropriate by the investigator.

Patients who were treated twice weekly for weeks 1-3 under a previous version of the protocol may, at the discretion of the investigator, have had the frequency of selinexor dosing increased to twice weekly for weeks 1-4. If there was no contraindicated toxicity, the selinexor dose may have been increased to 80 mg at Cycle 3.

02

Conditions studied

  • Richter's Transformation

Keywords

  • Richter's Transformation
  • Richter's Syndrome
  • Karyopharm
  • selinexor
  • KPT-330
  • SIRRT
  • CLL
03

In context

Lead sponsor

Karyopharm Therapeutics Inc is the lead sponsor of 37 studies on the registry; 4 are open to participants now.

Of its 18 completed or terminated interventional studies of FDA-regulated products, 16 (89%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Richter's Transformation, arising in the setting of prior CLL, documented by confirmed lymphoma, including large B-cell and immunoblastic variants.
  • All patients must have received at least one prior regimen for CLL, including cytotoxic chemotherapy, anti-CD20 monoclonal antibodies, a BTK inhibitor, or a PI3K inhibitor. Patients may have received high dose chemotherapy/ stem cell transplant (HDT/ASCT) or allogeneic hematopoietic stem cell transplant (allo SCT).
  • One or more measurable (> 1.5 cm in longest dimension) disease sites on CT (preferably PET/CT) or, if CT is , MRI (preferably PET/MRI) scans.
  • Objective documented evidence of disease progression at study entry
  • (ECOG) performance status score of ≤ 2

Exclusion criteria

Exclusion Criteria:

  • Radiation, chemotherapy, or immunotherapy or any other anticancer therapy ≤ 2 weeks prior to Cycle 1 Day 1, except ibrutinib which may be continued until one day prior to initiation of selinexor; radio-immunotherapy 4 weeks prior to Cycle 1 Day 1. Patients must have recovered to Grade ≤ 1 from adverse effects.
  • Prolymphocytic transformation
  • Less than 1 month since completion of stem cell transplantation or less than 3 months since completion of allogeneic stem cell transplantation
  • Major surgery within 4 weeks of C1D1
  • Impairment of GI function or GI disease that could interfere with the absorption of selinexor, including obstructed GI tract and uncontrolled vomiting or diarrhea.
  • Inability or unwillingness to take supportive medications including a centrally acting appetite stimulant (e.g., mirtazapine or olanzapine) and a peripherally acting appetite stimulant (e.g., low dose or megesterol acetate).
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
27 participants (actual)

Study arms

  • Experimental
    selinexor

    oral tablets * 10 mg \& 25 mg (bottled); or * 20 mg (blister pack)

    Drug: selinexor

Interventions

  • * 60 mg dose twice weekly, on Days 1 and 3 of weeks 1-4 of each 4-week cycle; dose may be increased to 80 mg after Cycle 1 unless clinically contraindicated (Protocol V.5.0). * 60 mg dose twice weekly on Days 1 and 3 of weeks 1-3 of each 4-week cycle; dose may be increased to 80 mg at Cycle 3 Day 1 unless clinically contraindicated (Protocol V.4.0). * 60 mg/m² dose, based on BSA, twice weekly, on Days 1 and 3 of weeks 1-3 of each 4-week cycle (Protocol V. 3.0). * 60 mg/m² dose, based on BSA, twice weekly, on Days 1 and 3 of weeks 1-4 of each 4-week cycle (Protocol V. \< 3.0).

    Also known as: KPT-330

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Overall Response (Overall Response Rate)

    Overall Response Rate (ORR) is defined as the point estimate of the percentage of patients who have complete response (CR) or partial response (PR). Disease response was assessed using the International Working Group (IWG) Response Criteria for non-Hodgkin's lymphoma (Cheson 2007), including assessment of lymph node, spleen and liver lesions by PET (positron emission tomography) scan and assessment of bone marrow biopsies by morphologic, immunohistochemistry, and flow cytometry tests. CR was defined as disappearance of all evidence of disease, and PR was defined as ≥ 50% regression of measurable disease and no new sites.

    Time frame: Assessments were performed at Screening or Cycle 1/Day 1 prior to dosing and on Cycle 3/Day 1 and alternate cycles thereafter until disease progression, study drug intolerability had been reached, study withdrawal, or death.

  2. Number of Participants With Complete Response (CR)

    Number of patients who achieved CR (complete disappearance of all detectable evidence of disease). Disease response was assessed using the International Working Group (IWG) Response Criteria for non-Hodgkin's lymphoma (Cheson 2007), including assessment of lymph node, spleen and liver lesions by PET (positron emission tomography) scan and assessment of bone marrow biopsies by morphologic, immunohistochemistry, and flow cytometry tests.

    Time frame: Assessments were performed at Screening or Cycle 1/Day 1 prior to dosing and on Cycle 3/Day 1 and alternate cycles thereafter until disease progression, study drug intolerability had been reached, study withdrawal, or death.

  3. Number of Participants With Partial Response (PR)

    Number of patients whose best overall response to study treatment was PR (≥ 50% regression of measurable disease and no new sites). Disease response was assessed using the International Working Group (IWG) Response Criteria for non-Hodgkin's lymphoma (Cheson 2007), including assessment of lymph node, spleen and liver lesions by PET (positron emission tomography) scan and assessment of bone marrow biopsies by morphologic, immunohistochemistry, and flow cytometry tests.

    Time frame: Assessments were performed at Screening or Cycle 1/Day 1 prior to dosing and on Cycle 3/Day 1 and alternate cycles thereafter until disease progression, study drug intolerability had been reached, study withdrawal, or death.

  4. Number of Participants With Stable Disease (SD)

    Number of patients whose best overall response to study treatment was SD (failure to attain criteria for CR or PR, or to meet criteria for PD). Disease response was assessed using the International Working Group (IWG) Response Criteria for non-Hodgkin's lymphoma (Cheson 2007), including assessment of lymph node, spleen and liver lesions by PET (positron emission tomography) scan and assessment of bone marrow biopsies by morphologic, immunohistochemistry, and flow cytometry tests.

    Time frame: Assessments were performed at Screening or Cycle 1/Day 1 prior to dosing and on Cycle 3/Day 1 and alternate cycles thereafter until disease progression, study drug intolerability had been reached, study withdrawal, or death.

  5. Number of Participants With Progressive Disease (PD)

    Number of patients whose best overall response to study treatment was PD (any new lesion or increase by ≥ 50% of previously involved sites from nadir). Disease response was assessed using the International Working Group (IWG) Response Criteria for non-Hodgkin's lymphoma (Cheson 2007), including assessment of lymph node, spleen and liver lesions by PET (positron emission tomography) scan and assessment of bone marrow biopsies by morphologic, immunohistochemistry, and flow cytometry tests.

    Time frame: Assessments were performed at Screening or Cycle 1/Day 1 prior to dosing and on Cycle 3/Day 1 and alternate cycles thereafter until disease progression, study drug intolerability had been reached, study withdrawal, or death.

  6. Number of Participants With Not Evaluable (NE) Response

    Number of patients who could not be assessed quantitatively for disease response for any reason.

    Time frame: Assessments were performed at Screening or Cycle 1/Day 1 prior to dosing and on Cycle 3/Day 1 and alternate cycles thereafter until disease progression, study drug intolerability had been reached, study withdrawal, or death.

Secondary outcomes

  1. Percentage of Participants With Disease Control (Disease Control Rate)

    Disease Control Rate (DCR) is defined as the percentage of patients who achieved CR, PR, or SD lasting for at least 8 weeks. CR was defined as disappearance of all evidence of disease. PR was defined as ≥ 50% regression of measurable disease and no new sites. SD was defined as failure to attain criteria for CR or PR, or to meet criteria for PD. Disease response was assessed using the International Working Group (IWG) Response Criteria for non-Hodgkin's lymphoma (Cheson 2007), including assessment of lymph node, spleen and liver lesions by PET (positron emission tomography) scan and assessment of bone marrow biopsies by morphologic, immunohistochemistry, and flow cytometry tests.

    Time frame: Assessments were performed at Screening or Cycle 1/Day 1 prior to dosing and on Cycle 3/Day 1 and alternate cycles thereafter until disease progression, study drug intolerability had been reached, study withdrawal, or death.

  2. Duration of Progression Free Survival (PFS)

    Number of days calculated from date of start of study therapy to date of progression based on IWG criteria, or date of death if progression did not occur. Patients who dropped out prior to study end without evidence of disease progression were censored at the day they were last known to be alive. Patients without documented disease progression or recurrence were censored at the date of last disease assessment. Disease response was assessed using the International Working Group (IWG) Response Criteria for non-Hodgkin's lymphoma (Cheson 2007), including assessment of lymph node, spleen and liver lesions by PET (positron emission tomography) scan and assessment of bone marrow biopsies by morphologic, immunohistochemistry, and flow cytometry tests. .

    Time frame: Assessments were performed at Screening or Cycle 1/Day 1 prior to dosing and on Cycle 3/Day 1 and alternate cycles thereafter until disease progression, study drug intolerability had been reached, study withdrawal, or death.

07

Results

Posted Feb 11, 2020
Limitations and caveats
The low number of formal objective responses (leading to the termination of the study following the first stage), coupled with the high number of censored observations, limited meaningful analyses and the ability to draw conclusions from the data.

Participant flow

This multicenter study was conducted at 30 clinical investigative sites in the United States and Europe. Of the 30 investigative sites, 15 sites enrolled a total of 27 patients in the study. * Date first patient enrolled: 14 November 2014 * Date last patient completed: 31 August 2016

Participant flow — Overall Study
MilestoneSelinexor 60 mg/m² (8 Doses/Cycle)Selinexor 60 mg (6 Doses/Cycle)Selinexor 60 mg (8 Doses/Cycle)
Started3158
Completed000
Not completed3158
Withdrew: Adverse event021
Withdrew: Death172
Withdrew: Disease progression113
Withdrew: Withdrawal by subject120
Withdrew: Patient's wish020
Withdrew: Sponsor terminated study011
Withdrew: Non-compliance001

Outcome measures

PrimaryPercentage of Participants With Overall Response (Overall Response Rate)

Overall Response Rate (ORR) is defined as the point estimate of the percentage of patients who have complete response (CR) or partial response (PR). Disease response was assessed using the International Working Group (IWG) Response Criteria for non-Hodgkin's lymphoma (Cheson 2007), including assessment of lymph node, spleen and liver lesions by PET (positron emission tomography) scan and assessment of bone marrow biopsies by morphologic, immunohistochemistry, and flow cytometry tests. CR was defined as disappearance of all evidence of disease, and PR was defined as ≥ 50% regression of measurable disease and no new sites.

Time frame:
Assessments were performed at Screening or Cycle 1/Day 1 prior to dosing and on Cycle 3/Day 1 and alternate cycles thereafter until disease progression, study drug intolerability had been reached, study withdrawal, or death.
Reported as:
Number · Percentage of participants
Percentage of Participants With Overall Response (Overall Response Rate)
Percentage of participantsSelinexor
Percentage of Participants With Overall Response (Overall Response Rate)4 (0.1 to 20.4)
PrimaryNumber of Participants With Complete Response (CR)

Number of patients who achieved CR (complete disappearance of all detectable evidence of disease). Disease response was assessed using the International Working Group (IWG) Response Criteria for non-Hodgkin's lymphoma (Cheson 2007), including assessment of lymph node, spleen and liver lesions by PET (positron emission tomography) scan and assessment of bone marrow biopsies by morphologic, immunohistochemistry, and flow cytometry tests.

Time frame:
Assessments were performed at Screening or Cycle 1/Day 1 prior to dosing and on Cycle 3/Day 1 and alternate cycles thereafter until disease progression, study drug intolerability had been reached, study withdrawal, or death.
Reported as:
Count of participants · Participants
Number of Participants With Complete Response (CR)
ParticipantsSelinexor
Number of Participants With Complete Response (CR)0
PrimaryNumber of Participants With Partial Response (PR)

Number of patients whose best overall response to study treatment was PR (≥ 50% regression of measurable disease and no new sites). Disease response was assessed using the International Working Group (IWG) Response Criteria for non-Hodgkin's lymphoma (Cheson 2007), including assessment of lymph node, spleen and liver lesions by PET (positron emission tomography) scan and assessment of bone marrow biopsies by morphologic, immunohistochemistry, and flow cytometry tests.

Time frame:
Assessments were performed at Screening or Cycle 1/Day 1 prior to dosing and on Cycle 3/Day 1 and alternate cycles thereafter until disease progression, study drug intolerability had been reached, study withdrawal, or death.
Reported as:
Count of participants · Participants
Number of Participants With Partial Response (PR)
ParticipantsSelinexor
Number of Participants With Partial Response (PR)1
PrimaryNumber of Participants With Stable Disease (SD)

Number of patients whose best overall response to study treatment was SD (failure to attain criteria for CR or PR, or to meet criteria for PD). Disease response was assessed using the International Working Group (IWG) Response Criteria for non-Hodgkin's lymphoma (Cheson 2007), including assessment of lymph node, spleen and liver lesions by PET (positron emission tomography) scan and assessment of bone marrow biopsies by morphologic, immunohistochemistry, and flow cytometry tests.

Time frame:
Assessments were performed at Screening or Cycle 1/Day 1 prior to dosing and on Cycle 3/Day 1 and alternate cycles thereafter until disease progression, study drug intolerability had been reached, study withdrawal, or death.
Reported as:
Count of participants · Participants
Number of Participants With Stable Disease (SD)
ParticipantsSelinexor
Number of Participants With Stable Disease (SD)6
PrimaryNumber of Participants With Progressive Disease (PD)

Number of patients whose best overall response to study treatment was PD (any new lesion or increase by ≥ 50% of previously involved sites from nadir). Disease response was assessed using the International Working Group (IWG) Response Criteria for non-Hodgkin's lymphoma (Cheson 2007), including assessment of lymph node, spleen and liver lesions by PET (positron emission tomography) scan and assessment of bone marrow biopsies by morphologic, immunohistochemistry, and flow cytometry tests.

Time frame:
Assessments were performed at Screening or Cycle 1/Day 1 prior to dosing and on Cycle 3/Day 1 and alternate cycles thereafter until disease progression, study drug intolerability had been reached, study withdrawal, or death.
Reported as:
Count of participants · Participants
Number of Participants With Progressive Disease (PD)
ParticipantsSelinexor
Number of Participants With Progressive Disease (PD)7
PrimaryNumber of Participants With Not Evaluable (NE) Response

Number of patients who could not be assessed quantitatively for disease response for any reason.

Time frame:
Assessments were performed at Screening or Cycle 1/Day 1 prior to dosing and on Cycle 3/Day 1 and alternate cycles thereafter until disease progression, study drug intolerability had been reached, study withdrawal, or death.
Reported as:
Count of participants · Participants
Number of Participants With Not Evaluable (NE) Response
ParticipantsSelinexor
Number of Participants With Not Evaluable (NE) Response11
SecondaryPercentage of Participants With Disease Control (Disease Control Rate)

Disease Control Rate (DCR) is defined as the percentage of patients who achieved CR, PR, or SD lasting for at least 8 weeks. CR was defined as disappearance of all evidence of disease. PR was defined as ≥ 50% regression of measurable disease and no new sites. SD was defined as failure to attain criteria for CR or PR, or to meet criteria for PD. Disease response was assessed using the International Working Group (IWG) Response Criteria for non-Hodgkin's lymphoma (Cheson 2007), including assessment of lymph node, spleen and liver lesions by PET (positron emission tomography) scan and assessment of bone marrow biopsies by morphologic, immunohistochemistry, and flow cytometry tests.

Time frame:
Assessments were performed at Screening or Cycle 1/Day 1 prior to dosing and on Cycle 3/Day 1 and alternate cycles thereafter until disease progression, study drug intolerability had been reached, study withdrawal, or death.
Reported as:
Number · Percentage of participants
Percentage of Participants With Disease Control (Disease Control Rate)
Percentage of participantsSelinexor
Percentage of Participants With Disease Control (Disease Control Rate)28.0 (12.1 to 49.4)
SecondaryDuration of Progression Free Survival (PFS)

Number of days calculated from date of start of study therapy to date of progression based on IWG criteria, or date of death if progression did not occur. Patients who dropped out prior to study end without evidence of disease progression were censored at the day they were last known to be alive. Patients without documented disease progression or recurrence were censored at the date of last disease assessment. Disease response was assessed using the International Working Group (IWG) Response Criteria for non-Hodgkin's lymphoma (Cheson 2007), including assessment of lymph node, spleen and liver lesions by PET (positron emission tomography) scan and assessment of bone marrow biopsies by morphologic, immunohistochemistry, and flow cytometry tests. .

Time frame:
Assessments were performed at Screening or Cycle 1/Day 1 prior to dosing and on Cycle 3/Day 1 and alternate cycles thereafter until disease progression, study drug intolerability had been reached, study withdrawal, or death.
Reported as:
Median · Days
Duration of Progression Free Survival (PFS)
DaysSelinexor
Duration of Progression Free Survival (PFS)38.0 (22.0 to 86.0)

Adverse events

Collected over Treatment-emergent AEs were collected from the first day of dosing (Cycle 1 Day 1) through the 30-day follow-up.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Selinexor 60 mg/m² (8 Doses/Cycle)1/3 (33.3%)3/3 (100%)3/3 (100%)
Selinexor 60 mg (6 Doses/Cycle)8/15 (53.3%)9/15 (60%)15/15 (100%)
Selinexor 60 mg (8 Doses/Cycle)2/8 (25%)5/8 (62.5%)7/8 (87.5%)
Most frequent serious events
Showing 10 of 26
Most frequent serious events
EventSelinexor 60 mg/m² (8 Doses/Cycle)Selinexor 60 mg (6 Doses/Cycle)Selinexor 60 mg (8 Doses/Cycle)
PneumoniaInfections and infestations1/30/151/8
AstheniaGeneral disorders1/30/150/8
FatigueGeneral disorders1/30/150/8
Mucosal InflammationGeneral disorders1/30/150/8
DehydrationMetabolism and nutrition disorders1/30/150/8
DyspnoeaRespiratory, thoracic and mediastinal disorders1/31/150/8
Acute Kidney InjuryRenal and urinary disorders1/30/150/8
SepsisInfections and infestations0/31/152/8
Deep Vein ThrombosisVascular disorders0/30/151/8
Clostridium Test PositiveInvestigations0/30/151/8
Most frequent other events
Showing 10 of 137
Most frequent other events
EventSelinexor 60 mg/m² (8 Doses/Cycle)Selinexor 60 mg (6 Doses/Cycle)Selinexor 60 mg (8 Doses/Cycle)
NauseaGastrointestinal disorders2/38/153/8
FatigueGeneral disorders2/34/152/8
Decreased AppetiteMetabolism and nutrition disorders2/35/152/8
HypotensionVascular disorders2/30/152/8
ThrombocytopeniaBlood and lymphatic system disorders1/38/155/8
DizzinessNervous system disorders0/31/154/8
VomitingGastrointestinal disorders1/37/151/8
PyrexiaGeneral disorders1/36/152/8
DiarrheaGastrointestinal disorders1/35/153/8
NeutropeniaBlood and lymphatic system disorders0/33/153/8

Baseline characteristics

Safety Population, consisting of all patients who received any amount of study medication.

Age, Continuous
Age, Continuous(years)Selinexor 60 mg/m² (8 Doses/Cycle)Selinexor 60 mg (6 Doses/Cycle)Selinexor 60 mg (8 Doses/Cycle)Total
Median68.0 (66 to 74)68.0 (41 to 77)69.0 (65 to 79)68.0 (41 to 79)
Sex: Female, Male
Sex: Female, Male(Participants)Selinexor 60 mg/m² (8 Doses/Cycle)Selinexor 60 mg (6 Doses/Cycle)Selinexor 60 mg (8 Doses/Cycle)Total
Female2349
Male112417
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Selinexor 60 mg/m² (8 Doses/Cycle)Selinexor 60 mg (6 Doses/Cycle)Selinexor 60 mg (8 Doses/Cycle)Total
Hispanic or Latino1102
Not Hispanic or Latino114823
Unknown or Not Reported1001
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Selinexor 60 mg/m² (8 Doses/Cycle)Selinexor 60 mg (6 Doses/Cycle)Selinexor 60 mg (8 Doses/Cycle)Total
American Indian or Alaska Native0000
Asian0000
Native Hawaiian or Other Pacific Islander0000
Black or African American0000
White315826
More than one race0000
Unknown or Not Reported0000
ECOG score
ECOG score(Participants)Selinexor 60 mg/m² (8 Doses/Cycle)Selinexor 60 mg (6 Doses/Cycle)Selinexor 60 mg (8 Doses/Cycle)Total
Score=00527
Score=136413
Score=20415
Missing0011
Weight
Weight(kg)Selinexor 60 mg/m² (8 Doses/Cycle)Selinexor 60 mg (6 Doses/Cycle)Selinexor 60 mg (8 Doses/Cycle)Total
Median56.5 (52.3 to 96.0)76.5 (51.9 to 115.5)73.05 (46.4 to 88.1)74.40 (46.4 to 115.5)
08

Study locations

17 sites
  • University of Arizona Cancer Center
    Tucson, Arizona 85724, United States
  • City of Hope National Medical Center
    Duarte, California 91010, United States
  • University of California-Los Angeles
    Santa Monica, California 90404, United States
  • Winship Cancer Institute / Emory University
    Atlanta, Georgia 30322, United States
  • Weill Cornell Medical College
    New York, New York 10065, United States
  • Ohio State University Comprehensive Cancer Center
    Columbus, Ohio 43202, United States
  • Huntsman Cancer Institute/University of Utah
    Salt Lake City, Utah 84112, United States
  • University of Ulm
    Ulm, Baden-Württemberg 89081, Germany
  • University Hospital of Cologne
    Koeln, 50937, Germany
  • Malopolskie Centrum Medyczne
    Kraków, 30-510, Poland
  • Copernicus Memorial Hospital, Department of Hematology
    Lodz, 93-513, Poland
  • Maria Skłodowska-Curie Institue of Oncology
    Warszawa, 02-034, Poland
  • Instituto Clinico Navarra, Pamplona
    Pamplona, Navarra 31008, Spain
  • Institut Català d'Oncologia Av.
    Barcelona, 08010, Spain
  • Hospital Vall Hebron
    Barcelona, 08035, Spain
  • The Royal Marsden NHS Foundation Trust
    Sutton, Surrey SM2 5PT, United Kingdom
  • Churchill Hospital: Cancer and Haematology Centre
    Oxford, OX3 8JL, United Kingdom
09

References and documents

Publications

  • Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, Coiffier B, Fisher RI, Hagenbeek A, Zucca E, Rosen ST, Stroobants S, Lister TA, Hoppe RT, Dreyling M, Tobinai K, Vose JM, Connors JM, Federico M, Diehl V; International Harmonization Project on Lymphoma. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007 Feb 10;25(5):579-86. doi: 10.1200/JCO.2006.09.2403. Epub 2007 Jan 22. PubMed 17242396 ↗

Individual participant data

Plan to share: Yes

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2014 to primary completion in Aug 2016, 21 months.

Results were first posted in Feb 2020, 3 years 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 13, 2014
First posted
May 15, 2014
StartActual
Nov 14, 2014
Primary completionActual
Aug 31, 2016
CompletionActual
Aug 31, 2016
Results first posted
Feb 11, 2020
Last update
Jan 26, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 26, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02138786
Responsible party
Sponsor
First posted
May 15, 2014
Start date
Nov 14, 2014
Primary completion
Aug 31, 2016
Completion
Aug 31, 2016
Results posted
Feb 11, 2020
Last update
Jan 26, 2023

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jan 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Selinexor

Start the discussion